AU:AGN Stock Latest News
Company AnnouncementsArgenica Advances Late-Stage Stroke Trial Plans for Xaranetide2w agoAGN
Company AnnouncementsArgenica strengthens scientific case for multi-target stroke drug xaranetide3w agoAGN
Company AnnouncementsArgenica sets 2026 AGM date and shifts to digital shareholder communications3w agoAGN
Company AnnouncementsArgenica Director Boosts Direct Shareholding in On-Market Trade1M agoAGN
Company AnnouncementsArgenica Sets 2026 AGM Date and Director Nomination Deadline1M agoAGN
Company AnnouncementsArgenica’s xaranetide concussion data earns international neurotrauma spotlight2M agoAGN
Company AnnouncementsArgenica Options Lapse Trims Potential Diluted Capital3M agoAGN
Company AnnouncementsArgenica Highlights Neuroprotection Strategy in New Investor Briefing3M agoAGN
Company AnnouncementsWHO Confirms International Generic Name for Argenica’s Lead Stroke Drug5M agoAGN
Company AnnouncementsArgenica Options Lapse Clarifies Capital Structure5M agoAGN
Company AnnouncementsArgenica Advances ARG-007 Stroke Program and Strengthens Funding for Phase 2b Trial6M agoAGNCompany AnnouncementsArgenica boosts cash reserves with $3.97m R&D rebate to advance stroke drug8M agoAGN
Company AnnouncementsArgenica Widens Half-Year Loss as ARG-007 Stroke Trial Spending Climbs9M agoAGN
Company AnnouncementsArgenica Wins EMA Paediatric Waiver, Streamlining EU Pathway for Stroke Drug ARG-0079M agoAGN
Company AnnouncementsArgenica’s AI Analysis Confirms ARG-007 Efficacy in Severe Stroke, Paving Way for Phase 2b Trial9M agoAGN
Company AnnouncementsArgenica Therapeutics Announces Departure of Director Di Angus10M agoAGN
Company AnnouncementsArgenica Chair Steps Down as Biotech Prepares for Next Growth Phase10M agoAGN
Company AnnouncementsArgenica’s ARG-007 Shows Promising Results in Severe Stroke Patients11M agoAGNCompany AnnouncementsArgenica’s ARG-007 Shows Promising Results in Preclinical Stroke Study11M agoAGN




